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Background: Metformin treatment has been the most recommended monotherapy of type 2 diabetes mellitus
(T2DM) for decades but is challenged by new antidiabetic drugs. This study conducted a meta-analysis of randomized
controlled trials (RCT) comparing the efficacy of metformin and glimepiride in monotherapy of T2DM.
Methods: A literature search for RCTs on glimepiride and metformin was conducted on the bibliographic databases,
including PubMed, Cochrane Library and ScienceDirect, from their inceptions to 25 Mar 2013. All RCTs were selected
according to pre-specified eligibility criteria. The quality of articles was assessed with the Cochrane’s risk of bias tool.
Statistical meta-analysis evaluated the overall effects and biochemical indices of T2DM. Sensitivity and subgroup
analyses evaluated the robustness and explained the heterogeneity of the results. Begg and Egger’s tests quantified
possible publication biases. Results were represented as “standard mean difference or odds ratio [95% confidence
internals] P value”.
Results: Fifteen RCTs with 1681 adult T2DM patients were included for meta-analysis. Metformin was not better
than glimepiride in overall efficacy in controlling the levels of HbA1c, postprandial blood sugar (PPBS), fasting
plasma insulin (FINS), systolic and diastolic blood pressures (SBP and DBP), and high density lipoprotein (HDL).
Metformin was only more effective than glimepiride in controlling the levels of total cholesterol (TC, 0.33 [0.03,
0.63], P = 0.03), low-density lipoprotein (LDL, 0.35 [0.16, 0.53], P = 0.0002) and triglycerides (TG, 0.26 [0.05, 0.46],
P = 0.01). Odds ratios of adverse events showed that glimepiride was more likely to induce hypoglycemia episodes
and metformin was with a higher risk of gastrointestinal upset.
Conclusion: Metformin was not significantly better than glimepiride in glycemic control of T2DM, suggesting that
glimepiride would be a good choice second to metformin in the monotherapy of T2DM.
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Metformin has been the most recommended monother-
apy of type 2 diabetes mellitus (T2DM) [1,2]. The UK
Prospective Diabetes Study (UKPDS) found metformin
more effective than chlorpropamide, glibenclamide and
insulin [3–5]. The American Diabetes Association (ADA)
recommended metformin as the first drug of choice for* Correspondence: siu@inf.ed.ac.uk
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reproduction in any medium, provided the ortreating T2DM patients, especially those who are over-
weight [2]. The UK National Institute for Health and
Clinical Excellence (NICE) recommended metformin if
the patients are at danger under hypoglycaemia [1]. The
latest recommendations of ADA [2] and NICE [1] were
updated with the results of UKPDS [6,7], post-trial moni-
toring of UKPDS [8], and systematic reviews of comparing
metformin with placebo, sulfonylureas and other anti-
diabetic drugs [7,9], as well as the randomized controlled
trials (RCTs) comparing metformin monotherapy with pio-
glitazone [10], metformin plus nateglinide [11], metformin. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ments [13]. A meta-analysis of RCTs on the efficacy of
metformin in treating T2DM [14] found metformin
lacking clear evidence for efficacy over the conven-
tional or placebo treatment. A recent literature review
suggested that metformin, albeit old, remained the best
treatment for T2DM [15] but the review was not a
systematic review or meta-analysis. It did not include
the latest RCTs comparing metformin and glimepiride
in monotherapy of T2DM.Figure 1.  Flow of
Identification
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Figure 1 Flow of study selection.Glimepiride is of the latest generation sulfonylureas
for treating T2DM [16]. It has a lower cardiovascular
risk than conventional sulfonylureas do [17–19]. Recent
RCTs found it comparable to metformin in treating
T2DM patients [20,21] including those who are not
responding well to non-glimepiride sulfonylureas [22,23].
Probably due to the late launch of glimepiride [24,25]
and lack of head-to-head comparative RCTs, early
UKPDS, ADA and NICE’s recommendations did not
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Table 1 Characteristics of included studies
Author (year) Country Age* Sample size Dosage Follow-up
period (weeks)Glimepiride Metformin Glimepiride Metformin Ref
Ling (2003) China Female 54 (8.3) 50 44 1-6 mg/day 750-1750 mg/day 12 [33]
Male 53 (9.2)
Ramachandran (2004) India 30-60 18 21 1-2 mg/day 250-850 mg/day 14 [34]
Derosa (2004) Italian 46-67 81 83 2-4 mg/day 2000-3000 mg/day 52 [35]
Gonzolez (2004) Mexico 40-65 37 33 2 mg/day 2000 mg/day 12 [36]
Rong (2004) China 42 (11) 98 100 4 mg/day 1500 mg/day 12 [22]
Tang (2004) China 35-70 33 29 1-2 mg/day 750-1500 mg/day 26 [37]
Yamanouchi (2005) Japan Metformin 54.7 (9.8) 37 39 1-2 mg/day 750 mg/day 52 [20]
Glimepiride 53 (9.2)
Ning (2006) China 35-70 51 50 1-6 mg/day 250 mg bid-750 mg tid 52 [38]
Wu (2007) China 30-70 40 30 1-6 mg/day 250-2000 mg tid 12 [39]
Xu (2007) China 35-70 34 34 1-6 mg/day 250 mg to maximum bid - [40]
Li (2007) China 32-70 35 33 2-6 mg/day 250-1500 mg bid 65 [41]
Wang (2009) China 45 (7) 49 50 4-6 mg/day 1500 mg/day 12 [23]
Rahman (2011) Pakistan Metformin 51.9 (14.1) 102 102 2-8 mg/day 500-2000 mg/day 52 [42]
Glimepiride 52 (15.4)
Yoon (2011) Korea 30-65 118 114 2 mg/day 500 mg/day 48 [21]
Wang (2011) China 33-70 68 68 2 mg/day 500 mg bid 12 [43]
* presented in range or mean (standard deviation).
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findings that sulfonlyureas had increased risks in
hypoglycemia, weight gain and cardiovascular issues.
Recent cohort studies confirmed the increased
cardiovascular risks of glimepiride [26] but did no car-
diovascular harm to the patients with diagnosed coronary
artery disease [27]. This study aimed to compare the
efficacy between metformin and glimepiride in monother-
apy of T2DM through a meta-analysis and supply the
evidence that was missing from previous reviews [9,11]





BMI 10 988 0.50
SBP 5 615 0.22
DBP 5 615 0.23
FPG 14 1611 0.03
HbA1c 13 1543 0.02
PPBS 11 1099 0.18
TC 9 887 0.16
HDL 9 887 0.24
LDL 6 702 0.02
TG 9 887 0.05
FINS 10 1019 0.41Methods
Eligibility criteria
Inclusion criteria
This study included the RCTs comparing glimepiride
with metformin as monotherapy of T2DM. Participants
in the RCTs were adult patients suffering from T2DM.
Outcome measures of the treatment of T2DM included
BMI (body mass index), SBP (systolic blood pressure),
DBP (diastolic blood pressure), FPG (fasting plasma
glucose), HbA1c (glycosylated hemoglobin level), PPBS
(postprandial blood sugar), TC (total cholesterol), HDLHeterogeneity Overall effect
I2 P-value SMD [95% CI] P-value
92% <0.00001 -0.06 [-0.53, 0.40] 0.79
86% <0.0001 0.39 [-0.06, 0.83] 0.09
87% <0.00001 0.34 [-0.12, 0.79] 0.15
47% 0.03 -0.02 [-0.16, 0.12] 0.80
41% 0.06 0.01 [-0.13, 0.14] 0.91
81% <0.00001 -0.27 [-0.56, 0.01] 0.06
79% <0.0001 0.33 [0.03, 0.63] 0.03
85% <0.00001 0.11 [-0.25, 0.46] 0.56
29% 0.21 0.35 [0.16, 0.53] 0.0002
54% 0.03 0.26 [0.05, 0.46] 0.01
91% <0.00001 0.07 [-0.35, 0.50] 0.73
Table 3 Cochrane’s risk of bias

















Ling (2003)[33] U U U U L U U
Ramachandran (2004)[34] U U U U L U U
Derosa (2004)[35] U U U U L U U
Gonzolez (2004)[36] U L L L L U U
Rong (2004)[22] U U U U L U U
Tang (2004)[37] U U U U L U U
Yamanouchi (2005)[20] L L L U L U U
Ning (2006)[38] U U U U L U U
Wu (2007)[39] U U U U L U U
Xu (2007)[40] U U U U L U U
Li (2007)[41] U U U U L U U
Wang (2009)[21] U U U U L U U
Rahman (2011)[42] U U U U L U U
Yoon (2011)[21] U U U U L U U
Wang (2011)[43] U U U U L U U
Note: L, low risk of bias; U, unclear risk of bias; H, high risk of bias.
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TG (triglycerides) and FINS (fasting plasma insulin).
Exclusion criteria
This study excluded the RCTs with the participants who
were non-responders to metformin or glimepiride and
received dosages exceeded the upper recommended limit
(metformin: 2550 mg daily; glimepiride: 8 mg daily) [28].
The RCTs of extremely small sample size (fewer than 10
patients) were also excluded.
Search and selection of studies
Bibliographical databases, including PubMed, Cochrance
Library, Science Direct, China Academic Journals Web
Publishing Database, China Master Theses Full-text
Database and China Doctor Theses Full-text DatabaseFigure 2 Cochrane’s risk of bias.on the China National Knowledge Infrastructure (CNKI),
WanFang Data and Google, were searched from their in-
ceptions to 25 Mar 2013.
Search strategies were specified in the working lan-
guages of databases, although the terminologies in
searching Chinese and English databases were equiva-
lent. Basically, the articles with the terms “glimepiride”
and “metformin” in titles, abstracts, and keywords were
retriered. Specific search strategies were:
PubMed: “Glimepiride” and “Metformin” in Abstract or
Title; Cochrane Llibrary: “Glimepiride” and “Metformin”
in Title, Abstract or Keywords; Science Direct:
“Glimepiride” and “Metformin” in Abstract, Title, or
Keywords; China Academic Jounrnals Web Publishing
Database, China Doctor Theses Full-text Database and
ChinaMaster Theses Full-text Database: ‘Title =Glimepiride






T2 I2 P-value SMD [95% CI] P-value
BMI 4 605 0.05 65% 0.03 0.21 [-0.06, 0.49] 0.13
FPG 8 1228 0.01 30% 0.18 0.09 [-0.04, 0.23] 0.18
HbA1c 8 1228 0.03 56% 0.03 0.06 [-0.12, 0.23] 0.52
PPBS 6 792 0.00 0% 0.59 -0.01 [-0.15, 0.13] 0.85
TC 3 504 0.22 90% <0.0001 0.56 [0.00, 1.12] 0.05
HDL 3 504 0.18 88% 0.0002 -0.27 [-0.78, 0.24] 0.30
LDL 3 504 0.01 21% 0.28 0.41 [0.21, 0.61] <0.0001
TG 3 504 0.00 0% 0.61 0.13 [-0.05, 0.30] 0.16
FINS 5 698 0.44 93% <0.00001 0.37 [-0.23, 0.98] 0.22
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Abstract = Glimepiride * Metformin’ (in Chinese); Wan
Fang: ‘Title All “Glimepiride Metformin” or Keywords All
“Glimepiride Metformin” or Abstract All “Glimepiride
Metformin”’ (in Chinese).
Two groups of reviewers (three reviewers in each
group) independently performed the literature search
and selection. The results from one group were cross-Table 5 Sensitivity analysis based on drug treatment before t
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participants who used other











FINS 5 483checked by the other group. Disagreements were re-
solved by group discussion.
Data extraction and quality assessment
Two reviewers (HZ, XZ) independently extracted data of
study characteristics and outcome measures from the
selected RCTs. The extracted data were cross-checked
before quality assessment according to the Cochrane’srials
ze
Heterogeneity Overall effect
T2 I2 P-value SMD [95% CI] P-value
0.50 92% <0.00001 -0.06 [-0.53, 0.40] 0.79
0.22 86% <0.0001 0.39 [-0.06, 0.83] 0.09
0.23 87% <0.00001 0.34 [-0.12, 0.79] 0.15
0.04 48% 0.03 0.01 [-0.15, 0.17] 0.91
0.03 46% 0.05 0.04 [-0.12, 0.19] 0.65
0.27 85% <0.00001 -0.32 [-0.69, 0.06] 0.10
0.16 79% <0.0001 0.33 [0.03, 0.63] 0.03
0.24 85% <0.00001 0.11 [-0.25, 0.46] 0.56
0.02 29% 0.21 0.35 [0.16, 0.53] 0.0002
0.05 54% 0.03 0.26 [0.05, 0.46] 0.01
0.58 92% <0.00001 0.11 [-0.44, 0.67] 0.69
0.05 56% 0.04 0.27 [0.03, 0.51] 0.03
0.22 87% 0.0004 0.60 [0.03, 1.16] 0.04
0.29 90% <0.0001 0.52 [-0.12, 1.16] 0.11
0.07 66% 0.004 -0.03 [-0.26, 0.19] 0.78
0.05 61% 0.02 -0.00 [-0.22, 0.22] 1.00
0.54 92% <0.00001 -0.60 [-1.28, 0.08] 0.08
0.18 82% <0.0001 0.38 [0.00, 0.76] 0.05
0.12 76% 0.0009 -0.14 [-0.46, 0.19] 0.41
0.04 56% 0.08 0.30 [0.05, 0.56] 0.02
0.00 0% 0.74 0.13 [-0.02, 0.28] 0.10
0.53 92% <0.00001 0.43 [-0.24, 1.10] 0.21
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discussion between the reviewers (HZ, XZ). A third
reviewer (SZ) was consulted when necessary.
Meta-analysis
Extracted data were transferred to Review Manager 5.2
[30] for meta-analysis with random-effects model. Nu-
meric outcome measures were represented in standard-
ized mean differences (SMD) or odds ratios (OR) and
their 95% confidence intervals (CI). Study heterogeneityTable 6 Sensitivity analysis based on the daily doses of metfo





































Note: “NA” stands for “not applicable”.was evaluated with T2 test and I2 statistics. P values
below 0.05 were considered statistically significant.
Sensitivity and subgroup analysis
Sensitivity analysis of the efficacy was performed on the
sample sizes, on whether the patients received prior anti-
diabetic treatments and on the daily dose of metformin.
Subgroup analysis was performed to explain the heterogen-
eity in terms of differences in follow-up periods and charac-
teristics of the participants.rmin
Heterogeneity Overall effect
T2 I2 P-value SMD [95% CI] P-value
0.01 22% 0.28 0.33 [0.09, 0.58] 0.007
0.00 0% 0.64 -0.02 [-0.31, 0.28] 0.92
0.00 0% 0.67 -0.06 [-0.36, 0.23] 0.69
0.02 34% 0.19 0.03 [-0.18, 0.24] 0.77
0.07 65% 0.02 0.14 [-0.15, 0.44] 0.34
0.04 46% 0.16 0.02 [-0.32, 0.36] 0.91
0.04 41% 0.18 0.32 [-0.03, 0.66] 0.07
0.00 0% 0.83 0.01 [-0.23, 0.26] 0.91
NA NA NA 0.19 [-0.15, 0.53] 0.27
0.00 0% 0.67 0.10 [-0.15, 0.34] 0.44
0.00 4% 0.37 0.22 [0.00, 0.43] 0.05
0.87 95% <0.00001 -0.36 [-1.13, 0.41] 0.36
0.17 85% 0.002 0.64 [0.12, 1.16] 0.02
0.19 86% 0.0009 0.60 [0.06, 1.14] 0.03
0.04 55% 0.02 -0.05 [-0.24, 0.14] 0.64
0.00 0% 0.87 -0.08 [-0.21, 0.04] 0.20
0.22 84% <0.00001 -0.37 [-0.73, -0.01] 0.04
0.24 85% <0.00001 0.34 [-0.09, 0.77] 0.12
0.39 90% <0.00001 0.14 [-0.39, 0.68] 0.59
0.02 32% 0.21 0.38 [0.17, 0.59] 0.0004
.0.08 67% 0.010 0.36 [0.07, 0.64] 0.02
0.71 95% <0.00001 -0.02 [-0.72, 0.67] 0.94
0.11 72% 0.06 0.16 [-0.38, 0.69] 0.56
0.42 91% 0.001 0.69 [-0.25, 1.63] 0.15
0.47 92% 0.0005 0.63 [-0.36, 1.63] 0.21
0.07 73% 0.02 0.02 [-0.35, 0.38] 0.93
0.00 0% 0.91 -0.16 [-0.34, 0.03] 0.10
0.00 0% 0.82 -0.11 [-0.29, 0.07] 0.24
0.01 17% 0.27 0.23 [-0.07, 0.52] 0.13
0.00 0% 0.48 0.06 [-0.20, 0.32] 0.64
NA NA NA 0.43 [0.12, 0.74] 0.006
0.04 49% 0.16 0.16 [-0.23, 0.55] 0.42
0.71 95% <0.00001 0.28 [-0.57, 1.13] 0.52
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Adverse events analysis was performed on the hypoglycemia,
gastrointestinal upset and overall side effects with their odds
ratios (OR) and 95% CI.
Publication bias
Funnel plots were generated to visualize possible publi-
cation bias. Begg and Egger’s tests using the package
“metafor” [31] with statistical software R [32] evaluated
the statistical significance of the publication bias.
Results
Included studies and their characteristics
Figure 1 shows the selection process of the studies. A
total of 1023 records were identified in accordance with
the search strategies from specific bibliographical data-
bases, i.e. PubMed (n = 208), Cochrance Library (n = 89),
Science Direct (n = 48), Chinese National Knowledge
Infrastructure (n = 267), WangFang (n = 206) and Google
(n = 205). Among the 440 records after removal of dupli-
cates, 27 records met the eligibility criteria. After
full-text assessment, 12 of 27 studies were excluded for
the reasons stated in Figure 1. As a result, 15 RCTs with
1681 participants were included for meta-analysis. The
characteristics of the included studies are shown in







12-24 weeks BMI 4 307 0.0
FPG 7 698 0.0
HbA1c 7 698 0.0
PPBS 2 297 0.0
TC 4 307 0.0
HDL 4 307 0.0
LDL 2 198 0.0
TG 4 307 0.0
FINS 5 542 0.0
48-60 weeks BMI 5 613 0.8
SBP 4 545 0.2
DBP 4 545 0.2
FPG 7 913 0.0
HbA1c 6 845 0.0
PPBS 3 333 0.0
TC 4 512 0.3
HDL 4 512 0.5
LDL 3 436 0.0
TG 4 512 0.1
FINS 4 409 1.1Overall effects
Meta-analysis was performed on the outcome measures
FPG, BMI, HbA1c, PPBS, TC, FINS, HDL, LDL, TG,
SBP and DBP. The SMD, 95% CI and P values for out-
comes between metformin and glimepiride are shown in
Table 2. The SMDs between metformin and glimepiride
were only statistically significant on TC (0.33 [0.03,
0.63], P = 0.03), LDL (0.35 [0.16, 0.53], P = 0.00002), and
TG (0.26 [0.05, 0.46], P = 0.01), indicating that efficacy of
metformin was statistically significant over glimepiride
in lipid metabolism indices. The differences in glycemic
control (e.g. HbA1c and PPBS) and cardiovascular indi-
ces (e.g. blood pressure) were not statistically significant.
As shown in Table 2, there were significant heterogene-
ities among studies in SBP (I2 = 86%, P < 0.0001), DBP
(I2 = 87%, P < 0.00001), PPBS (I2 = 81%, P < 0.00001), TC
(I2 = 79%, P < 0.0001), HDL (I2 = 86%, P < 0.00001) and
FINS (I2 = 91%, P < 0.00001). The heterogeneities
justified the use of random-effects model in meta-analysis.
Risk of bias across studies
Cochrane’s risk of bias tool was used to assess the RCT
quality (Table 3 and Figure 2). The attrition bias of all
included studies was low (few missing data). Other key
aspects among studies were mostly unclear in risk of
bias except two studies [20,36].Heterogeneity Overall effect
2 I2 P-value SMD [95% CI] P-value
0 0% 0.69 0.47 [0.24, 0.69] <0.0001
3 39% 0.13 -0.08 [-0.27, 0.12] 0.46
7 61% 0.02 -0.04 [-0.29, 0.20] 0.72
0 0% 0.78 -0.15 [-0.38, 0.08] 0.20
0 0% 0.98 0.50 [0.27, 0.72] <0.0001
0 0% 0.66 0.12 [-0.10, 0.35] 0.28
0 0% 0.36 0.28 [-0.00, 0.56] 0.05
0 0% 0.65 0.21 [-0.01, 0.44] 0.07
5 54% 0.07 0.05 [-0.21, 0.32] 0.69
4 96% <0.00001 -0.63 [-1.46, 0.20] 0.14
6 89% <0.00001 0.43 [-0.10, 0.96] 0.11
7 89% <0.00001 0.39 [-0.15, 0.93] 0.16
4 53% 0.05 0.03 [-0.17, 0.23] 0.77
0 0% 0.43 0.03 [-0.10, 0.17] 0.65
0 0% 0.95 -0.02 [-0.23, 0.20] 0.88
7 91% <0.00001 0.23 [-0.39, 0.86] 0.47
3 94% <0.00001 0.10 [-0.64, 0.84] 0.79
0 0% 0.80 0.48 [0.29, 0.67] <0.00001
4 80% 0.002 0.31 [-0.11, 0.73] 0.15
6 96% <0.00001 0.14 [-0.94, 1.21] 0.80
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Sensitivity analysis checked whether the overall effects
would be different if only the studies with the sample
size N ≥ 90 were included. As shown in Table 4, metfor-
min outperformed glimepiride only on LDL (0.41 [0.21,
0.61], P < 0.0001) in the studies with sample size N ≥ 90.
Other outcomes such as FPG, BMI, TC and TG did not
show significant difference between glimepiride and
metformin.
Sensitivity analysis also considered whether prior use
of anti-diabetic drugs would affect the RCT results.
Table 5 shows that only the effect of metformin on BMI
became statistically significant after excluding the studies
with participants who were non-responders to other sul-
fonyureas. The significance of the effects of metformin
on TC, LDL, TG and other aspects remained the same,
indicating the overall results on those aspects were
robust.
Sensitivity analysis tested whether the efficiency of
metformin would be different if the daily dose of metfor-
min was less than 1000 mg. Table 6 shows that metfor-
min outperformed glimepiride only on BMI (0.33 [0.09,Table 8 Subgroup analysis of different BMI




BMI < 27 BMI 7 618 0.83
SBP 3 381 0.09
DBP 3 381 0.10
FPG 7 788 0.02
HbA1c 6 720 0.00
PPBS 4 276 0.23
TC 5 455 0.37
HDL 5 455 0.57
LDL 3 340 0.08
TG 5 455 0.13
FINS 5 352 0.21
BMI≥ 27 BMI 3 370 0.13
SBP 2 234 0.42
DBP 2 234 0.47
FPG 2 300 0.00
HbA1c 2 300 0.27
PPBS 2 300 0.01
TC 3 370 0.02
HDL 3 370 0.00
LDL 2 300 0.00
TG 3 370 0.00
FINS 3 370 0.760.58], P = 0.007) with a low daily dose and on LDL (0.43
[0.12, 0.74], P = 0.006) with a relative high daily dose.
Subgroup analysis
Meta-analysis of the subgroups with different follow-up
periods (12-24 weeks and 48-60 weeks) showed that
metformin moderated BMI and TC better than glimepir-
ide in the shorter term while both drugs were equivalent
in performance in all aspects except LDL in the longer
term. As shown in Table 7, metformin performed better
than glimepiride on both BMI (0.47 [0.24, 0.69], P <
0.0001) and TC (0.50 [0.27, 0.72], P < 0.0001) in 12-24
weeks subgroup. In 48-60 weeks subgroup, metformin per-
formed better only on LDL (0.48 [0.29, 0.67], P < 0.00001).
Meta-analysis of the subgroups with BMI below or
above 27.5 (i.e. the norm in the countries where the in-
cluded RCTs were conducted) [44] was also conducted.
As shown in Table 8, metformin outperformed glimepir-
ide on control of FPG (0.34 [0.11, 0.57], P = 0.003), TC
(0.33 [0.08, 0.58], P = 0.01) and LDL (0.32 [0.08, 0.56],
P = 0.008) in the higher BMI subgroup (BMI ≥ 27.5).
However, in the lower BMI subgroup (BMI < 27.5)Heterogeneity Overall effect
I2 P-value SMD [95% CI] P-value
94% <0.00001 -0.27 [-0.98, 0.43] 0.45
72% 0.03 0.20 [-0.21, 0.60] 0.34
74% 0.02 0.15 [-0.27, 0.57] 0.48
38% 0.14 -0.05 [-0.24, 0.13] 0.57
0% 0.43 0.06 [-0.09, 0.20] 0.43
780% 0.003 -0.38 [-0.91, 0.15] 0.16
88% <0.00001 0.26 [-0.31, 0.84] 0.37
92% <0.00001 0.11 [-0.58, 0.81] 0.75
65% 0.06 0.30 [-0.09, 0.70] 0.14
72% 0.006 0.33 [-0.05, 0.71] 0.09
78% 0.001 -0.17 [-0.63, 0.29] 0.47
79% 0.009 0.31 [-0.15, 0.78] 0.18
91% 0.001 0.69 [-0.25, 1.63] 0.15
92% 0.0005 0.63 [-0.36, 1.63] 0.21
0% 0.82 0.34 [0.11, 0.57] 0.003
91% 0.001 0.17 [-0.58, 0.93] 0.65
29% 0.24 0.09 [-0.18, 0.36] 0.51
30% 0.24 0.33 [0.08, 0.58] 0.01
0% 0.71 0.03 [-0.18, 0.23] 0.79
6% 0.30 0.32 [0.08, 0.56] 0.008
4% 0.35 0.15 [-0.06, 0.36] 0.17
95% <0.00001 0.56 [-0.45, 1.57] 0.28
Table 9 Adverse events





T2 I2 P-value OR [95% CI] P-value
All side effects 8 1003 4.70 81% <0.00001 0.35 [0.06, 2.01] 0.24
Hypoglycemia 5 542 0.00 0% 0.77 4.94 [2.03, 11.99] 0.0004
Gastrointestinal upset 5 763 2.27 61% 0.04 0.07 [0.01, 0.37] 0.002
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http://www.dmsjournal.com/content/5/1/70metformin and glimepiride were not significantly different
in performance as determined by outcome measures.Adverse events
Eight out of 15 studies reported adverse events. As shown
in Table 9, glimepiride had more hypoglycemia episodes
than metformin did (4.94 [2.03, 11.99], P = 0.0004). Inci-
dents of gastrointestinal upset, including diarrhea, epigas-
tric discomfort, stomach pain and abdominal distension,
were reported more frequently in metformin group (0.07
[0.01, 0.37], P = 0.002). Overall, these two drugs had no
significant difference in side effects (0.35 [0.06, 2.01],
P = 0.24) among the included RCTs.Publication bias
Funnel plots were generated to visualize possible publi-
cation bias. Major outcomes FPG, BMI, HbA1c, PPBS,
TC, FINS, HDL, LDL, TG, SBP and DBP showed moder-
ate asymmetries across studies in the funnel plots, indi-
cating there was publication bias. A typical funnel plot is
shown in Figure 3. The statistical significance of the mod-
erate publication bias in sugar (FPG and PPBS) and lipid
(HDL and TG) indices was confirmed by the Begg’s rank
correlation test [45]. Egger’s linear regression method [46]
further confirmed the statistical significance of the publica-
tion bias in FPG towards metformin (Table 10), indicating
that the difference in glycemic control efficacy between
metformin and glimepiride was less than it seemed.Figure 3 Funnel plots of publication biases in FPG.Discussion
Metformin remains the most effective monotherapy of
T2DM while its advantages are diminishing among
newer anti-diabetic drugs. Past studies comparing the ef-
ficacy between metformin with sulfonylureas showed
that metformin was significantly better in controlling
HbA1c, FPG, BMI, LDL and TG [3–5,7]. Glimepiride is
a better sulphonylurea in treating T2DM [17–19,47,48].
The present meta-analytic study found that metformin
was not significantly better than glimepiride, particularly
in controlling HbA1c, FPG and BMI.
This meta-analysis supported that both metformin and
glimepiride was effective in treating T2DM for glycemic
control. Metformin performed better than glimepiride in
management of BMI and lipid metabolism indices but
the advantages of metformin were only significant in
short follow-up periods.
These results were deemed robust after evaluation by
sensitivity analysis that excluded small RCTs and the par-
ticipants who were non-responders to non-glimepiride
sulfonylureas or who received anti-diabetic treatment.
The differences between metformin and glimepiride be-
came insignificant in large RCTs. Even for treating the
patients who were not responding to conventional
(non-glimepiride) sulfonylureas, glimepiride and met-
formin were equivalent in glycemic control. This find-
ing could not be achieved by comparing sulfonylureas
(including glimepiride) as a group with metformin.Table 10 Results of Begg and Egger's tests
Outcome No. of
studies
Begg’s test Egger’s test
Z P-value Kendall’s tau P-value
BMI 10 -2.9174 0.0035 -0.0222 1.0000
SBP 5 -1.3229 0.1859 -0.2000 0.1867
DBP 5 -1.5941 0.1109 -0.4000 0.4833
FPG 14 -2.2496 0.0245 -0.4286 0.0356
HbA1c 13 -0.9014 0.3673 -0.2308 0.3062
PPBS 11 -2.2267 0.0260 -0.4182 0.0866
TC 9 -0.8218 0.4112 -0.0556 0.9195
HDL 9 2.2070 0.0273 0.5000 0.0752
LDL 6 -1.1076 0.2680 -0.3333 0.4694
TG 9 0.8232 0.04104 0.2778 0.3585
FINS 10 -0.8661 0.3864 -0.2444 0.3807
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http://www.dmsjournal.com/content/5/1/70Adverse events analysis showed that glimepiride had
more hypoglycemia episodes, in agreement with previ-
ous results that metformin was associated with less
hypoglycemia than sulphonylureas [3] and that metfor-
min had a higher risk of gastrointestinal upset [49–51].
The weight gain side effects were not significant in the
included RCTs, in consistency with the findings of previ-
ous studies [52] on the weight gain issue of glimepiride.
The daily dose of metformin affected the efficacy and
side effects of metformin. When the daily dose of metfor-
min was more than 1000 mg, the probability of gastro-
intestinal upset would be increased exponentially [53].
Sensitivity analysis on the daily doses of metformin
showed that metformin outperformed glimepiride only
on BMI with a low daily dose and on LDL with a rela-
tively high daily dose, but was not significantly better
than glimepiride on controlling HbA1c, FPG and Fins
in all daily doses.
Most of the included RCTs (13 out of 15 in this meta-
analysis) were conducted in Asia; thus, the Asian norm
of BMI for subgroup analysis was adopted. It seems that
Asian patients were less affected by the weight gain side
effect of glimepiride. Multi-country and multi-ethnic tri-
als are warranted to test whether glimepiride is more
suitable for Asian patients. Double-blind RCTs with lon-
ger follow-up periods should be conducted to assess
other side effects such as those on cardiovascular sys-
tem. It is encouraging that new clinical trials comparing
metformin and glimepiride for monotherapy of T2DM
have been registered [54]. Hence, proper updates on this
meta-analysis will be conducted in forthcoming years.
These results provide direct evidence to support ADA’s
and NICE’s recommendations to consider glimepiride as
one of the alternatives to metformin. Our meta-analysis
of the RCT results demonstrated that the advantages of
metformin over glimepiride were not always significant
particularly in Asian patients.Conclusion
Metformin and glimepiride were not significantly differ-
ent in glycemic control of T2DM, suggesting that glime-
piride would be a good choice second to metformin in
the monotherapy of T2DM.Abbreviations
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